Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial

Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial

Abstract Lynch syndrome (LS) is the most common cause of inherited colorectal cancer (CRC) and confers a high lifetime risk of CRC estimated to be up to 60%. Colonoscopy is recommended every 2 years in LS patients above the 20–25-year-old age bracket, and every year when colonic neoplasia has been d...

Full description

Bibliographic Details
Main Authors: Adil Soualy, David Deutsch, Mourad Benallaoua, Amal Ait-Omar, Florence Mary, Sabine Helfen, Marouane Boubaya, Vincent Levy, Robert Benamouzig, the AAS-Lynch group
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Trials
Online Access:http://link.springer.com/article/10.1186/s13063-020-04674-8

Internet

http://link.springer.com/article/10.1186/s13063-020-04674-8

Similar Items